La vendita allo scoperto per CBD Life Sciences dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di CBD Life Sciences. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

CBD Life Sciences (OTC:CBDL) Azioni, Report sulle vendite allo scoperto

CBD Life Sciences Inc is developing and marketing a line of cannabidiol-based organic products such as hemp drops, massage oils, recovery pain relief creams, anxiety and sleep solutions supplements, edibles, and a full line of pet products.

CBD LIFE SCIENCES INC by CBD Life Sciences Inc.

CBD Life Sciences Inc

News

PHUN

Phunware Unveils Hospitality AI Features To Enhance Mobile Guest Engagement, Plans Next-Gen App Innovation Talks

Bank of America Corporation Announced That It Will Redeem On June 12, 2025 All CHF375,000,000 Principal Amount Outstanding Of Its 0.2525% Senior Notes, Due June 12

Legal

BABA

Alibaba Concluded Some Products May Contain 3TG From Covered Countries, But Finds No Evidence The 3TG Financed Armed Groups

PPTA

Perpetua Resources Submits Formal Application To Export-Import Bank of the United States to Finance Stibnite Gold Project, Company Seeks $2B Financing; Aims To Boost U.S. Antimony Supply Amid Strategic Minerals Push

OKLO: 24% &#x7C; <a href="https://www.benzinga.com//node/45577517">Shares of OKLO and nuclear-linked stocks are trading higher amid report that President Trump to sign orders to boost nuclear power as soon as Friday.</a>
&nbsp;
BCAX: -36% &#x7C; <a href="https://www.benzinga.com//node/45576722">Bicara Therapeutics shares are trading lower after the company announced a publication of phase 1/1b trial data for ficerafusp alfa showing mixed results, with median survival still unreached and limited clarity on long-term efficacy.</a>
&nbsp;
IMMX: -20% &#x7C; <a href="https://www.benzinga.com//node/45577764">IMMX stock has given up its prior gain. Immix Biopharma shares were trading higher after the company announced the publication of cell therapy NXC-201 Abstract #7508, selected for oral presentation at the 2025 American Society of Clinical Oncology Annual Meeting.</a>

Movers

Trading Ideas

BCAX

IMMX

OKLO

Market-Moving News for May 23rd

Memorandum aims to integrate IonQ's quantum technology into South Korea's high-performance computing infrastructure, fueling R&amp;D, talent development, and ecosystem growth.
IonQ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NYSE">IONQ</a>), a leading commercial quantum computing and networking company, today announced the signing of a memorandum of understanding (MoU) with the Korea Institute of Science and Technology Information (KISTI), a leading national science and technology research institute and supercomputing center. The memorandum marks a significant expansion of IonQ's long standing relationship with South Korea's government, academic and industry sectors, aligning efforts intended to accelerate the national development of quantum science and industry.
Under the terms of the MoU, IonQ and KISTI will collaborate in four key areas: advanced infrastructure access, education, talent and knowledge exchange as well as collaboration to expand market opportunities. The two organizations will work together with the intent to introduce quantum systems into KISTI and plan to integrate these systems with KISTI's high-performance computing (HPC) infrastructure.
IonQ and KISTI also plan to collaborate on joint initiatives for talent upskilling including internships and training programs to strengthen the quantum computing research community in South Korea.

IONQ

IonQ Signs MoU With KISTI To Integrate IonQ's Quantum Technology Into South Korea's Computing Infrastructure, Fueling R&D, Talent Development, And Ecosystem Growth

HC Wainwright &amp; Co. analyst Yi Chen maintains Kala Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KALA#NASDAQ">KALA</a>) with a Buy and lowers the price target from $15 to $12.

Price Target

Analyst Ratings

KALA

HC Wainwright & Co. Maintains Buy on Kala Bio, Lowers Price Target to $12

KDLY

KindlyMD Changes NASDAQ Ticker To 'NAKA' Effective May 23, Reflecting Strategic Pivot Via Proposed Merger With Bitcoin-Focused Nakamoto

Instil And ImmuneOnco To Present Clinical Trial Updates And Insights On PD-(L)1xVEGF At ASCO Meeting

Pelareorep initiates a pro-inflammatory tumor microenvironment (TME) and induces innate and adaptive immune responses
New analyses confirm that pelareorep primes the TME to allow circulating tumor-infiltrating lymphocytes (TILs) in the blood to attack tumors
Pre-existing TIL clones in plasma may correlate positively with tumor shrinkage in pancreatic cancer
SAN DIEGO and CALGARY, AB, May 23, 2025 /PRNewswire/ -- Oncolytics Biotech&#xAE;&nbsp;Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCY#NASDAQ">ONCY</a>) (TSX:<a class="ticker" href="https://www.benzinga.com/stock/ONC#TSX">ONC</a>), a leading clinical-stage company specializing in immunotherapy for oncology, today announced new data from the Phase I/II GOBLET clinical trial in a poster presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The presentation highlights pelareorep's mechanism of action in pancreatic ductal adenocarcinoma (PDAC), offering new insights into how this immunotherapy stimulates multiple arms of the immune system and primes tumors for treatment.

ONCY

TSX:ONC

Oncolytics Biotech To Present New Data From Phase I/II GOBLET Clinical Trial At 2025 ASCO Annual Meeting

Invivyd, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVVD#NASDAQ">IVVD</a>), today announced that PEMGARDA&#xAE; (pemivibart), its investigational monoclonal antibody, has been added to the National Comprehensive Cancer Network&#xAE; (NCCN&#xAE;) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas. NCCN joins the Infectious Disease Society of America (IDSA) that updated its COVID-19 guidelines in August 2024 to recommend the use of PEMGARDA (pemivibart) for pre-exposure prophylaxis (PrEP) in moderately to severely immunocompromised adults and adolescents (aged 12 or older) at risk for progression to severe COVID-19 when predominant regional variants are susceptible to pemivibart.
This inclusion in the NCCN Guidelines recognizes PEMGARDA as a potential option for PrEP against COVID-19 in patients with B-cell malignancies. Immunocompromised patients may not mount an adequate immune response to vaccination.

IVVD

Invivyd's PEMGARDA Added to Cancer Guidelines for COVID-19 Protection in Immunocompromised Patients

TLSA

Tiziana Life Sciences Highlights Clinical Progress On Intranasal Alzheimer's Therapy With National Spotlight

Guidance

AIOT

Powerfleet Sees Prelim. FY25 Total Revenue ~$362.5M, Up 25% YoY; Sees FY26 Revenue Growth 20-25%

VEON Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VEON#NASDAQ">VEON</a>), a global digital operator ("VEON" or "the Company"), announces that it has now secured all regulatory approvals for its strategic partnership with Engro Corporation Limited ("Engro Corp") for the pooling and management of telecommunications infrastructure assets in Pakistan. The partnership, initially announced on December 5, 2024, is expected to enhance the efficiency of infrastructure and digital investments in the country, in line with Pakistan's digital ambitions.
Under the agreement, VEON's infrastructure assets housed under Deodar (Private) Limited, wholly owned by VEON through its subsidiary Pakistan Mobile Communications Limited, will vest into Engro Connect, an Engro Corp's subsidiary, via a scheme of arrangement. The companies have secured the necessary regulatory approvals, including from the Competition Commission of Pakistan, the Pakistan Telecommunication Authority, and the Islamabad High Court. The scheme of arrangement and related settlements are expected to be completed in June.

VEON

VEON Now Secures All Regulatory Approvals For Strategic Partnership With Engro Corp. For Pooling And Management Of Telecommunications Infrastructure Assets In Pakistan

OpenAI,&nbsp;Oracle Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>),&nbsp;Nvidia&nbsp;Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), Cisco Systems, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>), SoftBank Group (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SFTBF#OTC">SFTBF</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SFTBY#OTC">SFTBY</a>), and Group 42 Holding announced their <a target="_blank" href="https://www.benzinga.com/topic/project-stargate" rel="noreferrer noopener">partnership to build</a> Stargate UAE on Thursday.
Stargate UAE is a next-generation AI infrastructure cluster that will run in the newly established 5-gigawatt UAE–U.S. AI Campus <a target="_blank" href="https://group.softbank/en/news/press/20250522" rel="noreferrer noopener">in Abu Dhabi</a>.
G42 will build Stargate UAE, a 1-gigawatt compute cluster, and OpenAI and Oracle will operate it.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/earnings/25/05/45389466/softbank-books-3-6-billion-profit-on-arm-bytedance-gains-while-ai-bets-face-trade-policy-hurdles" rel="noreferrer noopener">SoftBank Books $3.6 Billion Profit On Arm, ByteDance Gains While AI Bets Face Trade Policy Hurdles</a>
The collaboration will also include Cisco, offering its zero-trust security and AI-ready connectivity, SoftBank Group, and Nvidia, which will supply the latest Nvidia Grace Blackwell GB300 systems.
The first 200-megawatt AI cluster will likely go live in 2026. Stargate UAE will accelerate scientific discovery and drive innovation across industries ranging from healthcare and energy to finance and transportation, fueling future economic growth and national development.
The full UAE–U.S. AI infrastructure campus, which spans 10 square miles, is the largest such deployment outside the U.S. It will provide 5 gigawatts of AI data center capacity and regional compute resources.
The facility will be powered by nuclear, solar, and natural gas to minimize carbon emissions. It will also house a science park driving innovation, talent development, and sustainable compute infrastructure.
Jensen Huang, founder and CEO of Nvidia, said, &#8220;AI is the most transformative force of our time. With Stargate UAE, we are building the AI infrastructure to power the country&#8217;s bold vision – to empower its people, grow its economy, and shape its future.&#8221;
Chuck Robbins, chair and CEO of Cisco, said, &#8220;Cisco is proud to join Stargate UAE to advance groundbreaking AI innovation in the UAE and around the world. By embedding our secure AI-optimized networking fabric for this international deployment, we&#8217;re building smart, secure and energy-efficient networks that will turn intelligence into impact at global scale.&#8221;
&#8220;By establishing the world&#8217;s first Stargate outside of the U.S. in the UAE, we&#8217;re transforming a bold vision into reality. This is the first major milestone in our OpenAI for Countries initiative, our effort to work with allies and partners to build AI infrastructure around the world. It&#8217;s a step toward ensuring some of this era&#8217;s most important breakthroughs, safer medicines, personalized learning, and modernized energy, can emerge from more places and benefit the world,&#8221; Sam Altman, co-founder and CEO of OpenAI stated.
A <a target="_blank" href="https://www.benzinga.com/media/25/04/44873349/openai-and-softbanks-stargate-considers-major-uk-investment-to-fuel-ai-growth" rel="noreferrer noopener">report in April</a> indicated that Stargate&nbsp;is weighing a&nbsp;future investment in&nbsp;the U.K. to build the global infrastructure needed to support advanced artificial intelligence models.
The&nbsp;OpenAI&nbsp;and&nbsp;SoftBank-backed AI infrastructure joint venture is raising $100 billion in investment in AI infrastructure projects, which could reach $500 billion over the next four years.&nbsp;
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/05/45572996/apple-likely-to-open-llms-integrate-gemini-on-iphone-at-wwdc-analyst" target="_blank" rel="noreferrer noopener">Apple Likely To Open LLMs, Integrate Gemini On iPhone At WWDC: Analyst</a></li>
</ul>
Photo by Gorodenkoff via Shutterstock

Tech

CSCO

NVDA

ORCL

SFTBF

SFTBY

Tech Titans Unite For Stargate UAE In AI Venture

Brookfield Corporation ("Brookfield") (NYSE:<a href="https://www.benzinga.com/stock/BN#NYSE">BN</a>, TSX:<a href="https://www.benzinga.com/stock/BN#TSX">BN</a>)&nbsp;today announced it has received approval from the Toronto Stock Exchange ("TSX") for the renewal of its normal course issuer bid to purchase up to 143,027,158 Class A Limited Voting Shares ("Class A Shares"), representing 10% of the public float of Brookfield's outstanding Class A Shares. Purchases under the bid will be made on the open market through the facilities of the TSX, the New York Stock Exchange ("NYSE"), and/or alternative trading systems. The period of the normal course issuer bid will extend from May 27, 2025 to May 26, 2026, or an earlier date should Brookfield complete its purchases. Brookfield will pay the market price at the time of acquisition for any Class A Shares purchased or such other price as may be permitted.

Buybacks

Brookfield Gets Green Light to Buy Back Up to 143M Shares Through 2026

LAZR

Luminar Enters Agreements For Repurchase Of $50M In 2026 Convertible Senior Notes

PSQ Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSQH#NYSE">PSQH</a>) ("PublicSquare," or the "Company"),America's leading marketplace and payments ecosystem valuing life, family, and liberty, today announced that James Rinn has been appointed Chief Financial Officer, effective June 1, 2025. Mr. Rinn, who has served as a board member and chair of the PublicSquare Audit Committee since July 2023, will succeed Brad Searle, who will transition to Senior Vice President of Finance for the Company's Brands Division. Mr. Rinn brings over 30 years of accounting leadership at public and private companies, having held multiple CFO roles throughout his career.
 &nbsp;

Management

PSQH

PSQ Holdings Names James Rinn CFO, Effective June 1, 2025; Rinn To Succeed Brad Searle, Who Will Transition To SVP Of Finance For Brands Division

Japanese government-bond yields are surging, and veteran Société Générale strategist Albert Edwards says the move could yank the rug from under U.S. stocks and Treasurys, warning of a potential "global financial-market Armageddon."
What Happened: "Both the U.S. Treasury and equity markets are vulnerable, having been inflated by Japanese flows of funds," Edwards wrote in a client note <a href="https://www.businessinsider.com/stock-market-crash-global-financial-market-armageddon-yen-carry-trade-2025-5">carried</a> by Business Insider, adding that an unwind of the yen carry trade could create "a loud sucking sound in U.S. financial assets."
&#8220;I would rank trying to understand and follow the surging long end of the JGB market as the number 1 most important thing for investors at the moment,&#8221; Edwards added.
Long-dated Japanese yields have blasted through multi-year highs after a string of weak debt auctions and the Bank of Japan's decision to let its vast bond holdings run off. The 40-year JGB now pays almost 3.7%, while the benchmark 10-year yield hovers near 1.53%, its loftiest level since 2011, reveals Reuters.
Japan is still the single-largest foreign holder of U.S. Treasurys, with about $1.13 trillion on its books. For decades, Japanese investors borrowed cheaply in yen and plowed the cash into higher-yielding U.S. debt and stocks, a strategy known as the carry trade. If rising JGB payouts lure that money home, demand for Treasurys could dry up just as Washington faces a record <a href="https://www.benzinga.com/25/05/45399783/gordon-johnson-warns-of-potential-liberation-day-20-as-30-year-treasury-yields-approach-5-amid-dollar-weakness">$8 trillion in refinancing needs</a> this year.
See also: <a href="https://www.benzinga.com/25/05/45582499/gary-black-slams-teslas-unsupervised-autonomous-driving-ahead-of-austin-robotaxi-launch-i-have-warned">Gary Black Slams Tesla&#8217;s Unsupervised Autonomous Driving Ahead Of Austin Robotaxi Launch: &#8216;I Have Warned…&#8217;</a>
Governor Kazuo Ueda has <a href="https://www.benzinga.com/markets/25/01/42995151/bojs-kazuo-ueda-signals-rate-hikes-japanese-bond-yields-rise-to-14-year-high-what-the-recent-past-tells-us-about-impact-on-us-markets">already lifted</a> short-term rates above zero and signaled further hikes, while the BOJ is "significantly" scaling back its ¥6 trillion monthly bond-buying program — moves that analysts call de-facto quantitative tightening. Foreign investors now hold a majority of newly issued JGBs, so less central-bank support is amplifying volatility at the long end of the curve.
Why It Matters: Rising Japanese yields are pushing global term premiums higher, says Reuters, propelling the U.S. 30-year Treasury above 5% for the first time since 2008 and rekindling equity-valuation jitters. Edwards argues that BOJ quantitative easing was "pivotal" to inflated U.S. tech valuations; its reversal could be a game-changer.
Analysts at Wellington and Kitco warn that a rushed carry-trade unwind could dump Treasurys, lift the dollar's volatility and even drive haven demand into gold.
Image via Shutterstock
Read next: <a href="https://www.benzinga.com/news/global/25/05/45582741/g7-targets-chinas-state-driven-trade-tactics-without-naming-it-pledging-action-against-nonmarket-practices">G7 Targets China&#8217;s State-Driven Trade Tactics Without Naming It, Pledging Action Against &#8216;Nonmarket Practices&#8217;</a>

Bonds

Markets

Japan Bonds Surge Sparks Wall Street Bear's Warning Of 'Global Armageddon,' Calls JGB Long End 'Most Important Thing' For Investors To Track

The Goodyear Tire &amp; Rubber Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GT#NASDAQ">GT</a>) on Thursday disclosed a deal to divest the majority of its <a href="https://www.benzinga.com/pressreleases/25/05/n45575257/goodyear-announces-sale-of-chemical-business">Goodyear Chemical business</a> to Gemspring Capital Management, LLC.
As per the terms of its divestiture, Gemspring Capital will acquire Goodyear Chemical for around $650 million in cash at closing, pending customary post-closing adjustments.
The acquisition covers two operational plants in Houston and Beaumont, Texas, along with a research and development center in Akron, Ohio.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/price-target/25/05/45572508/goodyear-tire-rubber-gets-jpmorgan-boost-as-restructuring-tariffs-align" rel="noreferrer noopener">Goodyear Tire &amp; Rubber Gets JPMorgan Boost As Restructuring, Tariffs Align</a>
Goodyear will maintain ownership of its Chemical facilities in Niagara Falls, New York, and Bayport, Texas, as well as the rights to the products manufactured at those sites.
Goodyear Chemical, a major synthetic rubber manufacturer with a diverse product range in North America, serves markets including automotive aftermarket, consumer, and industrial sectors.
This transaction stems from a strategic review of the Chemical business, undertaken as part of Goodyear&#8217;s Forward transformation plan.
The transaction is expected to close by late 2025, pending regulatory approval and other customary closing conditions.
Goodyear plans to use the proceeds from the sale to reduce its debt and fund key initiatives under its Goodyear Forward transformation strategy.
Mathew Wallace, managing director at Gemspring, stated, &#8220;Goodyear Chemical is an industry leader, underpinned by deep customer relationships, a mission-critical product portfolio, a track record of innovation, and incredibly talented employees.&#8221;
Tesham Gor, a Gemspring executive advisor who is expected to become CEO of the Business, added, &#8220;As a standalone entity, the Business will be well positioned to accelerate product development, expand its relationships with existing and new customers globally, deliver sustainable solutions, continue to invest in its people, and drive growth and innovation through commercial, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/n45575702/gemspring-capital-to-acquire-goodyear-chemical" rel="noreferrer noopener">technical, and operational excellence</a>.&#8221;
As of March 31, 2025, Goodyear had $8.10 billion in long-term debt (Long Term Debt and Finance Leases, Operating Lease Liabilities) and held $978 million in cash and equivalents.
Investors can gain exposure to the stock via&nbsp;Invesco S&amp;P Midcap 400 Pure Value ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RFV#NYSE">RFV</a>) and First Trust Small Cap Value AlphaDEX Fund (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FYT#NASDAQ">FYT</a>).
Price Action: GT shares are trading higher by 0.63% to $11.20 premarket at last check Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/25/04/44641614/as-tariff-panic-hits-stocks-these-5-names-defied-the-odds" target="_blank" rel="noreferrer noopener">As Trump Tariffs Rippled Through The Markets, Goodyear Tire And These Stocks Defied The Downturn — Here&#8217;s Why</a></li>
</ul>
Photo by Fabio Pagani via Shutterstock

Equities

Large Cap

Asset Sales

Rydex ETF Trust S&P Midcap 400 Pure Value ETF

Goodyear Offloads Chemical Business To Reduce Debt, Fund Growth

Press Releases

CBD Life Sciences Inc. (CBDL) Announces Its Official Launch on Groupon.com

CBDL Launches New Mushroom Supplement Drink & Smoothie Bar

CBD Life Sciences Inc. (CBDL) Launches Mushroom Powder Capsules

CBD Life Sciences Inc. (CBDL) Gears Up for Cave Creek Bike Week 2025

CBD Life Sciences Inc. (CBDL) Launches Passion Fuel Cordyceps Complex - A Powerful Sexual Enhancement Supplement

CBD Life Sciences Inc. (CBDL) Powers Forward with Disruptive Brain-Boosting Mushroom Applications

CBD Life Sciences Inc. (CBDL) Company Online Sales Up 500%

CBD Life Sciences Inc. (CBDL) Announces Groundbreaking 100MG Full Spectrum CBD Gummy Geared Toward Mental Health & Focus

CBD Life Sciences Inc. (CBDL) Announces New Manufacturing Deal With A Columbian Company

CBD Life Sciences Inc. (CBDL) Announces New Manufacturing Deal With A Southwest-Based Company

CBDL

CBD Life Sciences

Comments

CBD Life Sciences

Vendite allo scoperto

CBD Life Sciences (OTC:CBDL) Azioni, Report sulle vendite allo scoperto

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO